Immix Biopharma (IMMX) Stock Price, News & Analysis

Immix Biopharma logo
$7.17 -0.03 (-0.40%)
As of 01:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Immix Biopharma Stock (NASDAQ:IMMX)

Advanced

Key Stats

Today's Range
$7.05
▼
$7.43
50-Day Range
$7.20
▼
$12.83
52-Week Range
$3.78
▼
$15.10
Volume
357,234 shs
Average Volume
1.31 million shs
Market Capitalization
$601.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.14
Consensus Rating
Moderate Buy

Company Overview

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues.

The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use.

Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.

AI Generated. May Contain Errors.

Immix Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

IMMX MarketRank™: 
2.28615139018 of 5 stars

Immix Biopharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 594th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immix Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Immix Biopharma has a consensus price target of $24.00, representing about 238.7% upside from its current price of $7.09.

  • Amount of Analyst Coverage

    Immix Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Immix Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Immix Biopharma are expected to decrease in the coming year, from ($0.75) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immix Biopharma is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immix Biopharma is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immix Biopharma has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    22.57% of the float of Immix Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Immix Biopharma has a short interest ratio ("days to cover") of 9.24.
  • Change versus previous month

    Short interest in Immix Biopharma has recently increased by 5.07%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Immix Biopharma does not currently pay a dividend.

  • Dividend Growth

    Immix Biopharma does not have a long track record of dividend growth.

  • News Sentiment

    Immix Biopharma has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Immix Biopharma this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Immix Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    30.30% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    11.26% of the stock of Immix Biopharma is held by institutions.

  • Read more about Immix Biopharma's insider trading history.
Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMMX Stock News Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Headlines

IMMX Stock Analysis - Frequently Asked Questions

Immix Biopharma's stock was trading at $5.23 at the start of the year. Since then, IMMX stock has increased by 35.5% and is now trading at $7.0860.

Immix Biopharma, Inc. (NASDAQ:IMMX) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.00.

Immix Biopharma (IMMX) raised $23 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share.

Immix Biopharma's top institutional investors include State Street Corp (4.62%), Marshall Wace LLP (2.59%), Aberdeen Group plc (1.14%) and Blue Owl Capital Holdings LP (0.84%). Insiders that own company stock include Ilya M Rachman, Jason Hsu, Gabriel S Morris and Carey Ng.
View institutional ownership trends
.

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include Tesla (TSLA), NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Biofrontera (BFRI), Genprex (GNPX) and Intel (INTC).

Company Calendar

Last Earnings
11/12/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMMX
CIK
1873835
Fax
N/A
Employees
21
Year Founded
2012

Price Target and Rating

High Price Target
$30.00
Low Price Target
$19.00
Potential Upside/Downside
+235.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-24.93%
Return on Assets
-23.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
33.72
Quick Ratio
33.72

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.00 per share
Price / Book
1.80

Miscellaneous

Outstanding Shares
83,810,000
Free Float
49,863,000
Market Cap
$602.59 million
Optionable
Optionable
Beta
0.29

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:IMMX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners